Semaglutide 7.2 mg ~15% loss week 32

Semaglutide 7.2 mg and orforglipron were back in the discussion on May 19 after physicians on X highlighted two numbers patients often ask about: how fast weight loss shows up, and how much of it can be maintained. The posts pointed to recent trial data rather than new company announcements. One figure came from Novo Nordisk’s STEP UP trial of higher-dose semaglutide. The other came from Eli Lilly’s ATTAIN-MAINTAIN study of oral orforglipron after prior injectable-driven weight loss. ### Where does the “about 15% by week 32” semaglutide figure come from? The Lancet published the STEP UP phase 3b trial of once-weekly semaglutide 7.2 mg in adults with obesity in 2025. The trial tested a higher dose than the currently familiar 2.4 mg regimen and reported mean weight loss at 72 weeks of about 19% on the treatment-regimen analysis, with larger losses in adherent-patient analyses. (thelancet.com) The “about 15% by week 32” figure appears to be a timeline snapshot from the semaglutide 7.2 mg weight-loss curve rather than the trial’s primary endpoint. Novo Nordisk’s medical site and coverage of STEP UP emphasize the week-72 result, while the social-media discussion focused on the earlier point on the curve. The main verified topline from STEP UP is that the higher dose produced greater average weight loss than semaglutide 2.4 mg and placebo over 72 weeks. (thelancet.com) ### What did STEP UP actually show at the end of the trial? JAMA reported that in roughly 1,400 adults with obesity, average weight reduction at 72 weeks was 19% with semaglutide 7.2 mg, 16% with semaglutide 2.4 mg and 4% with placebo. JAMA also said about 31% of participants on 7.2 mg lost at least a quarter of their body weight, compared with 15% on 2.4 mg. (novomedlink.com) Novo Nordisk said in its FDA-filing announcement that people treated with semaglutide 7.2 mg achieved 20.7% weight loss after 72 weeks in the adherent-treatment analysis, versus 17.5% with semaglutide 2.4 mg and 2.4% with placebo. The company also said 33.2% of participants on 7.2 mg lost 25% or more of body weight in that analysis. (jamanetwork.com) ### What is the orforglipron maintenance claim referring to? Nature Medicine published the ATTAIN-MAINTAIN phase 3b trial in May 2026, describing oral orforglipron as a way to preserve weight loss after patients had already reduced weight on injectable incretin therapy. The study was presented at the European Congress on Obesity and was randomized and placebo-controlled. (prnewswire.com) Medical Xpress, summarizing the paper, reported that in one cohort participants maintained a mean 74.7% of prior body-weight reduction with orforglipron versus 49.2% with placebo. The same report said a secondary analysis looked at the proportion of patients who maintained 80% or more of weight lost previously. That is close to the 78%-82% range cited in the May 19 social-media posts, though the exact percentage depends on the cohort and analysis method being referenced. (nature.com) ### How does that differ from orforglipron’s original weight-loss trial? The New England Journal of Medicine published ATTAIN-1 in September 2025 as a 72-week obesity trial in adults without diabetes. In that study, the highest orforglipron dose, 36 mg, produced an average 11.2% reduction in body weight versus 2.1% with placebo, and 36.0% of participants on 36 mg lost at least 15% of body weight. (medicalxpress.com) Eli Lilly has also stressed convenience as a distinguishing feature. In company materials and trial publications, orforglipron is described as a once-daily oral GLP-1 that can be taken without food or water restrictions, a point that has featured prominently in physician and patient discussion. ### What should readers take from the May 19 posts? (mediacenteratypon.nejmgroup-production.org) May 19’s posts were recirculating published trial data, not announcing a new head-to-head result between semaglutide 7.2 mg and orforglipron. The semaglutide number refers to the pace of loss on a higher-dose injectable curve, while the orforglipron number refers to maintenance after earlier weight loss, not initial loss from baseline. (mediacenteratypon.nejmgroup-production.org) April 1, 2026, was a separate milestone for Lilly, when the FDA approved Foundayo, the brand name for orforglipron, for chronic weight management in adults with obesity or overweight with weight-related medical problems. Novo Nordisk’s higher-dose semaglutide data remain anchored to STEP UP and related regulatory filings and publications. (investor.lilly.com) (thelancet.com)